StreetInsider.com News Articles

Enliven Therapeutics (ELVN) PT Raised to $62 at Mizuho

Tue, 02 Jun 2026 06:42:17 -0400

(Updated - June 2, 2026 6:42 AM EDT)

Mizuho analyst Salim Syed raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $62.00 (from $45.00) while maintaining a Outperform rating.

The analyst commented: "On 6/11 at the European Hematology Association (EHA) Congress, we'll get updated ELVN-001 Ph1b (ENABLE) data, specifically, ~20 additional patients and ~3 months of additional follow-up since the January 2026 update, which was also in the EHA abstract. Recall, the focus here is the 80mg QD (proposed go-forward) dose and MMR-achieved-by-24-weeks measure. We want to see this maintain or increase (even if slightly) vs the prior released 38% (essentially

Enliven Therapeutics (ELVN) PT Raised to $62 at Mizuho

Tue, 02 Jun 2026 06:42:17 -0400

(Updated - June 2, 2026 6:42 AM EDT)

Mizuho analyst Salim Syed raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $62.00 (from $45.00) while maintaining a Outperform rating.

Enliven Therapeutics to Present at Upcoming Investor Conferences

Thu, 21 May 2026 16:05:00 -0400

BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences:

TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHA
Format: Fireside Chat
Date: Wednesday, May 27
Time: 2:30 p.m. ET

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, June 4
Time: 11:40 a.m. ET

The fireside chats will be webcast live and can be accessed by visiting the investor relations

Enliven Therapeutics to Present at Upcoming Investor Conferences

Thu, 21 May 2026 16:05:00 -0400

TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHA
Format: Fireside Chat
Date: Wednesday, May 27
Time: 2:30 p.m. ET

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, June 4
Time: 11:40 a.m. ET

The fireside chats will be webcast live and can be accessed by visiting the investor relations

Enliven Therapeutics to Present at Upcoming Investor Conferences

Thu, 21 May 2026 16:05:00 -0400

TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHA
Format: Fireside Chat
Date: Wednesday, May 27
Time: 2:30 p.m. ET

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, June 4
Time: 11:40 a.m. ET

The fireside chats will be webcast live and can be accessed by visiting the investor relations

Enliven Therapeutics to Present at Upcoming Investor Conferences

Thu, 21 May 2026 16:05:00 -0400

TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHA
Format: Fireside Chat
Date: Wednesday, May 27
Time: 2:30 p.m. ET

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, June 4
Time: 11:40 a.m. ET

The fireside chats will be webcast live and can be accessed by visiting the investor relations

Form 4 Enliven Therapeutics, For: May 18 Filed by: Collins Helen Louise

Wed, 20 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260520/26528656.html

Form 4 Enliven Therapeutics, For: May 18 Filed by: Collins Helen Louise

Wed, 20 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260520/26528656.html

Form 144 Enliven Therapeutics, Filed by: Collins Helen Louise

Mon, 18 May 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260518/26514281.html

Form 144 Enliven Therapeutics, Filed by: Collins Helen Louise

Mon, 18 May 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260518/26514281.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Polar Capital Holdings Plc

Fri, 15 May 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26508019.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Polar Capital Holdings Plc

Fri, 15 May 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26508019.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Vestal Point Capital, LP

Fri, 15 May 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260515/26507736.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Vestal Point Capital, LP

Fri, 15 May 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260515/26507736.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 15 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260515/26506950.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 15 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260515/26506950.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Commodore Capital LP

Fri, 15 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26506756.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Commodore Capital LP

Fri, 15 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26506756.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Fairmount Funds Management LLC

Fri, 15 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26506786.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Fairmount Funds Management LLC

Fri, 15 May 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260515/26506786.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Polar Capital Holdings Plc

Fri, 15 May 2026 09:12:00 -0400

si-local-file:///var/storage/secattach/20260515/26500605.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Polar Capital Holdings Plc

Fri, 15 May 2026 09:12:00 -0400

si-local-file:///var/storage/secattach/20260515/26500605.html

Enliven Therapeutics to present ELVN-001 trial data at EHA congress

Tue, 12 May 2026 09:54:02 -0400

Enliven Therapeutics Inc. (NASDAQ: ELVN) announced it will present updated Phase 1 clinical trial data for ELVN-001 in chronic myeloid leukemia patients at the European Hematology Association 2026 Congress on June 11 in Stockholm.

The data from the ongoing ENABLE Phase 1 trial shows a cumulative major molecular response rate of 47% in the 80 mg once-daily Phase 1b cohort, with 38% of patients achieving major molecular response by 24 weeks. In patients who previously received asciminib, the cumulative major molecular response rate was 52%.

As of December 22, 2025, 141 patients were enrolled across dose levels from 10-160 mg once daily,

Enliven Therapeutics to present ELVN-001 trial data at EHA congress

Tue, 12 May 2026 09:54:02 -0400

As of December 22, 2025, 141 patients were enrolled across dose levels from 10-160 mg once daily,

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

Tue, 12 May 2026 09:53:00 -0400

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort

In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeks

ELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks

EHA presentation will include updated data with additional patients and longer treatment duration

BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Enliven